Merrell Dow Pharmaceuticals Inc. v. Thompson

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023

Retrieved on: 
Thursday, October 19, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Merrell Dow Pharmaceuticals Inc. v. Thompson, Webcast, PIN, ACAD, Pharmaceutical industry, Financial adviser, Cryptocurrency

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets.
  • Acadia’s management team will also host a conference call and webcast on November 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
  • The conference call will be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until December 4, 2023.
  • Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Health, Webcast, Merrell Dow Pharmaceuticals Inc. v. Thompson, U.S.–Canada Team Tournament (Go), Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open.
  • Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.
  • The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.
  • A replay of the webcast will be available on Aurinia’s website.

Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI

Retrieved on: 
Tuesday, September 26, 2023
Veterinary, Medical Devices, Surgery, Infectious Diseases, Hospitals, Practice Management, Biotechnology, Pharmaceutical, Health, Oncology, Pain management, Central nervous system, Merrell Dow Pharmaceuticals Inc. v. Thompson, Post-traumatic stress disorder, CNS, Pharmaceutical industry

Anthony P. Mack , Chairman and CEO will be giving the presentation.

Key Points: 
  • Anthony P. Mack , Chairman and CEO will be giving the presentation.
  • The 2023 LD Micro Main Event XVI will run from October 3rd to the 5th at the Luxe Sunset Boulevard Hotel in Los Angeles.
  • Presentations will run from 8:00 AM PT to 5:00 PM PT on the 3rd and 4th, with a half day on Thursday the 5th.
  • This three-day event will feature around 200 companies, presenting in half-hour increments, and attending private meetings with investors.

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

Retrieved on: 
Thursday, September 21, 2023
Biotechnology, Pharmaceutical, Health, Faculty, University of Alberta, National Association Medical Staff Services, University, Doctor of Pharmacy, Medical laboratory, National Science Board, University of Alberta Faculty of Pharmacy and Pharmaceutical Sciences, Roche, Merrell Dow Pharmaceuticals Inc. v. Thompson, EDGAR, Associate, Chemistry, SEDAR, Lupus nephritis, Walter, Immunosuppression, Chair, Pharmaceutical industry, Management, Pharmacy, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board.
  • MKT Capital Ltd. (together with its affiliates, “MKT Capital”) submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board.
  • In connection with Dr. Foster’s appointment, MKT Capital has entered into a cooperation agreement with Aurinia.
  • A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR.

Virpax Pharmaceuticals Updates on Litigation

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Pain management, Court, Central nervous system, Merrell Dow Pharmaceuticals Inc. v. Thompson, Post-traumatic stress disorder, Judgement, CNS, Pharmaceutical industry, Insurance

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received a ruling on the lawsuit filed by Scilex Pharmaceuticals (NASDAQ:SCLX) and Sorrento Therapeutics, the now bankrupt majority owner of Scilex Pharmaceuticals.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received a ruling on the lawsuit filed by Scilex Pharmaceuticals (NASDAQ:SCLX) and Sorrento Therapeutics, the now bankrupt majority owner of Scilex Pharmaceuticals.
  • The Court found in favor of the plaintiffs (on all but three counts deemed to have been waived).
  • However, no damages judgment was specified in the ruling which called for additional proceedings to determine the remedy.

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 30, 2023
Biotechnology, Pharmaceutical, Health, Neurology, ACAD, Morgan Stanley, Merrell Dow Pharmaceuticals Inc. v. Thompson, TD, Pharmaceutical industry, Cryptocurrency

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
    Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Pharmaceutical, Finance, Surgery, Health, Medical Devices, Infectious Diseases, Professional Services, Pain management, Central nervous system, Merrell Dow Pharmaceuticals Inc. v. Thompson, Post-traumatic stress disorder, Conference, CNS, Pharmaceutical industry

ET.

Key Points: 
  • ET.
  • Management will also be hosting in-person and virtual one-on-one meetings during the conference.
  • Event: Virpax Presentation at the H.C. Wainwright 25th Annual Global Investment Conference
    Time: On Demand from 7:00 a.m.
  • ET daily
    For more information on the H.C. Wainwright BioConnect Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to [email protected] or call (917) 923-8541.

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Pharmaceutical, Health, Inflammation, Amgen, Korn Ferry, Johnson & Johnson, Partnership, University, LLM, Sucampo Pharmaceuticals, Woman, MBA, Merrell Dow Pharmaceuticals Inc. v. Thompson, Doctor of Philosophy, Sale, Science, Rutgers University, Organization, Chemistry, Business administration, Nephrology, MD, Janssen Pharmaceuticals, Sangamo Therapeutics, Acceleron Pharma, Growth, Therapy, Family, Management, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors.
  • The selection process included working with Korn Ferry, a global organizational talent firm, to identify and screen multiple qualified candidates.
  • “We are thrilled to have Dr. Smith and Mr. Bailey join Aurinia’s Board of Directors.
  • Both Dr. Smith and Mr. Bailey have served on boards that have had successful outcomes, including sales, mergers, and partnerships.

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results

Retrieved on: 
Monday, July 24, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Webcast, PIN, Arrowhead Pharmaceuticals, Merrell Dow Pharmaceuticals Inc. v. Thompson, Cryptocurrency

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal 2023 third quarter ended June 30, 2023.
  • Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm .
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

Retrieved on: 
Thursday, July 20, 2023
Health, FDA, Research, Pharmaceutical, Science, Biotechnology, Webcast, U.S.–Canada Team Tournament (Go), Merrell Dow Pharmaceuticals Inc. v. Thompson, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open.
  • Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.
  • The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com .
  • A replay of the webcast will be available on Aurinia’s website.